制药产业创新激励政策研究的述评与展望
发布时间：2019-06-14 07:36
【摘要】：基于制药产业激励与规制并存的典型特征,将制药产业创新激励政策划分为激励性政策和规制性政策两大类。通过国内外相关文献的梳理,就价格管制政策、医保支付政策、集中采购规制以及创新药研发激励政策对制药产业创新激励影响的研究进展进行了梳理和述评,提出未来该领域的研究应立足于中国的管理实践,从非对称信息、多种政策工具对创新药研发激励的综合作用机制,以及引入新的研究范式等三个方面进行突破。
[Abstract]:Based on the typical characteristics of the coexistence of incentive and regulation in pharmaceutical industry, the innovation incentive policy of pharmaceutical industry is divided into incentive policy and regulatory policy. Through combing the relevant literature at home and abroad, this paper combs and reviews the research progress of price control policy, medical insurance payment policy, centralized procurement regulation and innovative drug R & D incentive policy on innovation incentive in pharmaceutical industry, and puts forward that the future research in this field should be based on the management practice of China, from asymmetric information and various policy tools to the comprehensive action mechanism of innovative drug research and development incentive. And the introduction of new research paradigm and other three aspects of breakthrough.
【作者单位】： 天津工业大学管理学院;天津理工大学管理学院;南开大学商学院;
【基金】：国家社会科学基金项目(15BGL074) 天津市哲学社会科学基金(TJGL15-035) 天津市宣传文化“五个一批”人才项目(2015RC05)
【分类号】：R951
本文编号：2499230
[Abstract]:Based on the typical characteristics of the coexistence of incentive and regulation in pharmaceutical industry, the innovation incentive policy of pharmaceutical industry is divided into incentive policy and regulatory policy. Through combing the relevant literature at home and abroad, this paper combs and reviews the research progress of price control policy, medical insurance payment policy, centralized procurement regulation and innovative drug R & D incentive policy on innovation incentive in pharmaceutical industry, and puts forward that the future research in this field should be based on the management practice of China, from asymmetric information and various policy tools to the comprehensive action mechanism of innovative drug research and development incentive. And the introduction of new research paradigm and other three aspects of breakthrough.
【作者单位】： 天津工业大学管理学院;天津理工大学管理学院;南开大学商学院;
【基金】：国家社会科学基金项目(15BGL074) 天津市哲学社会科学基金(TJGL15-035) 天津市宣传文化“五个一批”人才项目(2015RC05)
【分类号】：R951
【相似文献】
相关期刊论文 前1条
1 高军;侯玉岭;赵一帆;;药品集中招标采购给中国制药产业灾难性打击 全国人大代表刘群谈药价虚高背后的问题[J];首都医药;2014年07期
，本文编号：2499230
本文链接：https://www.wllwen.com/jingjilunwen/chanyejingjilunwen/2499230.html
